Latest News
Transgene Secures a EUR 20m Revolving Credit Facility with Natixis
21 March 2019 - - French biotechnology company Transgene (Euronext Paris: TNG) (PAR: TNG) has secured a EUR 20m revolving credit facility with Natixis, the French Corporate and Investment bank, the company said.

The credit facility will ...
Puma Biotechnology Presents Interim Results from the Phase II SUMMIT Trial of Neratinib for HER2 (ERBB2) Mutant, Metastatic Cervical Cancer
21 March 2019 - - Updated results from the cervical cancer cohort of SUMMIT, an ongoing Phase II basket trial examining the efficacy of neratinib in HER2-mutated cancers, were reported at the Society of Gynecologic Oncology 2019 annual meeting in Hon...
FDA Approves Genentech's Tecentriq in Combination with Chemotherapy for the Initial Treatment of Adults with Extensive-Stage Small Cell Lung Cancer
21 March 2019 - - The US Food and Drug Administration approved Tecentriq (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of adults with extensive-stage small cell lung cancer (...
Novo Nordisk submits two NDAs to US FDA for oral semaglutide and sNDA for Ozempic
21 March 2019 - Global healthcare company Novo Nordisk A/S (CPH:NOVOB) announced on Wednesday the submission of two New Drug Applications (NDAs) to the US Food and Drug Administration (FDA) for oral semaglutide, a once-daily glucagon-like peptide-1 (...
Boehringer Ingelheim Files FDA and EMA Regulatory Submission for Nintedanib in Systemic Sclerosis Associated ILD
21 March 2019 - - German drugmaker Boehringer Ingelheim has filed for regulatory approval of nintedanib in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD) with the FDA and EMA, the company said.

Nintedanib...